Design and synthesis of pyrimidine molecules endowed with thiazolidin-4-one as new anticancer agents

被引：37

作者：

Rashid, Mohd ^{[1
]}

Husain, Asif ^{[1
]}

Shaharyar, Mohammad ^{[1
]}

Mishra, Ravinesh ^{[1
]}

Hussain, Afzal ^{[1
]}

Afzal, Obaid ^{[1
]}

机构：

[1] Jamie Hamdard Hamdard Univ, Dept Pharmaceut Chem, Fac Pharm, New Delhi 110062, India

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2014年 / 83卷

关键词：

In-vitro anticancer activity; NCI 60 cell line; CDK; 2; enzyme; Thiazolidin-4-one; NATIONAL-CANCER-INSTITUTE; CYCLIN-DEPENDENT KINASES; TRIAZOLO-THIADIAZOLES; BEARING OXADIAZOLE; DRUG DISCOVERY; DERIVATIVES; INHIBITORS; ANTIBACTERIAL; CHEMOTHERAPY; OLOMOUCINE;

D O I：

10.1016/j.ejmech.2014.06.033

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Design and synthesis of new pyrimidine derivatives clubbed with thiazolidin-4-one from 4-(2-chlorophenyl)-6-(2,4-dichlorophenyl)pyrimidin-2-amine and their in vitro anticancer activities were screened at National Cancer Institute (NCI), USA against full NCI 60 cell lines. Compound 2 (NSC: 765735) exhibited remarkable growth inhibition at single dose (10 mu M) and encourage chosen for broadcast at 10-fold dilutions of five different concentrations (0.01, 0.1, 1, 10 and 100 mu M). The compound 2 was found better quality for Lung cancer cell line (HOP-92) by viewing growth inhibition (GI(50) 0.52) and no cytotoxicity seen (LC50 > 100). Molecular docking study was performed using Maestro 9.0 (Schrodinger Inc. USA) to provide binding mode into binding sites of CDK2. Compound 2 could be used as a lead compound for developing new potential anticancer agents. (C) 2014 Elsevier Masson SAS. All rights reserved.

引用

页码：630 / 645

页数：16

共 62 条

[51]

Salem FS, 2011, VET ITAL, V47, P89

[52] The NCI60 human tumour cell line anticancer drug screen [J].

Shoemaker, Robert H. .

NATURE REVIEWS CANCER, 2006, 6 (10) :813-823

[53] Selective in vivo and in vitro effects of a small molecule inhibitor of cyclin-dependent kinase 4 [J].

Soni, R ;

O'Reilly, T ;

Furet, P ;

Muller, L ;

Stephan, C ;

Zumstein-Mecker, S ;

Fretz, H ;

Fabbro, D ;

Chaudhuri, B .

JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (06) :436-+

[54] Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine [J].

Stresemann, Carlo ;

Lyko, Frank .

INTERNATIONAL JOURNAL OF CANCER, 2008, 123 (01) :8-13

[55] Troxacitabine in acute leukemia [J].

Swords, R. ;

Giles, F. .

HEMATOLOGY, 2007, 12 (03) :219-227

[56] Synthesis and anti-inflammatory activities of some thiazolo[3,2-a]pyrimidine derivatives [J].

Tozkoparan, B ;

Ertan, M ;

Kelicen, P ;

Demirdamar, R .

FARMACO, 1999, 54 (09) :588-593

[57]

Volm M, 1998, ANTICANCER RES, V18, P2905

[58] Capecitabine: A review [J].

Walko, CM ;

Lindley, C .

CLINICAL THERAPEUTICS, 2005, 27 (01) :23-44

[59]

Wang SQ, 2004, CHINESE CHEM LETT, V15, P885

[60] Preclinical antitumor activity of 4′-thio-β-D-arabinofuranosylcytosine (4′-thio-ara-C) [J].

Waud, WR ;

Gilbert, KS ;

Shepherd, RV ;

Montgomery, JA ;

Secrist, JA .

CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 51 (05) :422-426

← 1 2 3 4 5 6 7 →